C5 Inhibition in Secondary Thrombotic Microangiopathies: A Yet Unresolved Question. [PDF]
Werion A, Rondeau E.
europepmc +1 more source
Two cases of proteasome inhibitors related thrombotic microangiopathies and literature review. [PDF]
An N, Shi P, Chen C.
europepmc +1 more source
Hematological and Renal Involvement in Thrombotic Microangiopathies
Thrombotic microangiopathies (TMA) are life-threatening conditions associated with thrombocytopenia, microangiopathic hemolytic anemia and organ damage.
Gembillo G., Santoro D., Peritore L.
core +1 more source
Clinical Spectrum and Differential Diagnosis of Adult Thrombotic Microangiopathies: Real-World Experience from a Tertiary Referral Center. [PDF]
Kırkayak NP +4 more
europepmc +1 more source
Complement activation in secondary thrombotic microangiopathies. [PDF]
Morelle J +14 more
europepmc +1 more source
Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre. [PDF]
Grall M +14 more
europepmc +1 more source
Ocular manifestations of primary thrombotic microangiopathies : a descriptive systematic review. [PDF]
Baker M +8 more
europepmc +1 more source
Role of C5 inhibition in Idiopathic Inflammatory Myopathies and Scleroderma Renal Crisis-Induced Thrombotic Microangiopathies. [PDF]
Gouin A +10 more
europepmc +1 more source
Emerging Novel Etiology for Thrombotic Microangiopathies: COVID-19 Infection
Aliriza Pektas +5 more
core +1 more source
Urine Protein/Creatinine Ratio in Thrombotic Microangiopathies: A Simple Test to Facilitate Thrombotic Thrombocytopenic Purpura and Hemolytic and Uremic Syndrome Diagnosis. [PDF]
Burguet L +10 more
europepmc +1 more source

